Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | TGM2 | P21980 | 7/20 | 0.49 |
| ▸ | F13A1 | P00488 | 6/20 | 0.49 |
| ▸ | TGM1 | P22735 | 6/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3360042 | 0.95 | MEN1 (0.51) | USP2SMN1; SMN2TGM2F13A1TGM1 | |
| SCHEMBL18294 | 0.85 | USP2 (0.69) | USP2SMN1; SMN2HPGDEPHX2MEN1 | |
| SCHEMBL698803 | 0.85 | USP2 (0.69) | USP2SMN1; SMN2HPGDEPHX2MEN1 | |
| SCHEMBL25871062 | 0.85 | USP2 (0.51) | USP2SMN1; SMN2TGM2F13A1TGM1 | |
| SCHEMBL7423533 | 0.85 | USP2 (0.55) | USP2SMN1; SMN2TGM2F13A1HPGD | |
| SCHEMBL16121827 | 0.84 | USP2 (0.44) | USP2SMN1; SMN2TGM2F13A1TGM1 | |
| SCHEMBL16099877 | 0.84 | NR1H2 (0.42) | USP2SMN1; SMN2TGM2F13A1TGM1 | |
| SCHEMBL19629272 | 0.84 | USP2 (0.50) | USP2SMN1; SMN2TGM2F13A1TGM1 | |
| SCHEMBL19629273 | 0.84 | USP2 (0.50) | USP2SMN1; SMN2TGM2F13A1TGM1 | |
| SCHEMBL18914398 | 0.83 | USP2 (0.53) | USP2SMN1; SMN2TGM2F13A1TGM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070935-A1 | BISPHOSPHONATE LIPIDS, LIPID NANOPARTICLE COMPOSITIONS COMPRISING THE SAME, MINERAL TISSUE-ADSORBED COMPOSITIONS THEREOF, AND METHODS OF USE THEREOF | UNIV PENNSYLVANIA (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4116338-B1 | HYDROPHILIC POLYMERIC PARTICLES AND METHODS FOR MAKING SAME | LIFE TECHNOLOGIES CORP (US) | 2025-06-11 | — | — | EP | disclosed |
| EP-4479397-A1 | PYRIMIDINEDIONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF | CMG Pharmaceutical Co., Ltd. (KR) | 2024-12-25 | — | — | EP | disclosed |
| US-12122859-B2 | Hydrophilic polymeric particles and methods for making and using same | LIFE TECHNOLOGIES AS (NO) | 2024-10-22 | — | — | US | disclosed |
| US-11897874-B2 | Compounds and methods for modulating Interleukin-2-inducible T-cell kinase | CORVUS PHARMACEUTICALS, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| US-20240026051-A1 | CATIONIC CYCLIC AMINE AND AMPHIPATHIC TRANSFECTION REAGENTS | MIRUS BIO LLC | 2024-01-25 | — | — | US | disclosed |
| CN-114133394-B | Compound selectively aiming at activity of cell cycle dependent kinase 12, preparation method and medical application | 赛诺哈勃药业（成都）有限公司 | 2023-12-08 | — | — | CN | disclosed |
| US-20230348423-A1 | PYRIMIDINEDIONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF | CMG PHARMACEUTICAL CO., LTD. (KR) | 2023-11-02 | — | — | US | disclosed |
| US-20230348423-A1 | PYRIMIDINEDIONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF | CMG PHARMACEUTICAL CO., LTD. (KR) | 2023-11-02 | — | — | US | disclosed |
| EP-3684776-B1 | HETEROCYCLYL SUBSTITUTED PYRROLOPYRIDINES THAT ARE INHIBITORS OF THE CDK12 KINASE | UNIV NOTTINGHAM (GB) | 2023-11-01 | — | — | EP | disclosed |
| US-20130210991-A1 | Hydrophilic Polymeric Particles and Methods for Making and Using Same | Life Technologies Corporation (US) | 2013-08-15 | — | — | US | disclosed |
| US-20100003338-A1 | Micelles for delivery of nitric oxide | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2010-01-07 | — | — | US | disclosed |
| WO-2010002450-A2 | MICELLES FOR DELIVERY OF NITRIC OXIDE | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (CH) | 2010-01-07 | — | — | WO | disclosed |
| US-7229996-B2 | Rifamycin derivatives | CUMBRE PHARMACEUTICALS INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-7229996-B2 | Rifamycin derivatives | CUMBRE PHARMACEUTICALS INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-7229996-B2 | Rifamycin derivatives | CUMBRE PHARMACEUTICALS INC. (US) | 2007-06-12 | — | — | US | disclosed |
| EP-1781670-A1 | RIFAMYCIN DERIVATIVES FOR TREATING MICROBIAL INFECTIONS | Cumbre Pharmaceuticals Inc. (US) | 2007-05-09 | — | — | EP | disclosed |
| CN-1898238-A | Oxazolidinone-quinolone hybrid antibiotics | MORPHOCHEM AG FUER KOM (DE) | 2007-01-17 | — | — | CN | disclosed |
| WO-2006012470-A1 | RIFAMYCIN DERIVATIVES FOR TREATING MICROBIAL INFECTIONS | CUMBRE PHARMACEUTICALS INC. (US) | 2006-02-02 | — | — | WO | disclosed |
| US-20060019985-A1 | Rifamycin derivatives | CUMBRE INC. (US) | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019985-A1 | Rifamycin derivatives | RIF1, NQO1, MRM1 | USP2 4422/4885SMN1; SMN2 3758/4885TGM2 2394/4885 |
| US-20100003338-A1 | Micelles for delivery of nitric oxide | NOS2, NOS1, NOS3 | USP2 385/4885SMN1; SMN2 333/4885TGM2 2740/4885 |
| US-20260070935-A1 | BISPHOSPHONATE LIPIDS, LIPID NANOPARTICLE COMPOSITIONS COMPRISING THE SAME, MINERAL TISSUE-ADSORBED COMPOSITIONS THEREOF, AND METHODS OF USE THEREOF | BCR, PHOSPHO1, BST2 | USP2 4096/4885SMN1; SMN2 2383/4885TGM2 1909/4885 |
| US-20240026051-A1 | CATIONIC CYCLIC AMINE AND AMPHIPATHIC TRANSFECTION REAGENTS | SLC7A1, PARN, PARG | USP2 4121/4885SMN1; SMN2 3613/4885TGM2 2750/4885 |
| US-11897874-B2 | Compounds and methods for modulating Interleukin-2-inducible T-cell kinase | IL2, NFATC1, IL2RA | USP2 720/4885SMN1; SMN2 4518/4885TGM2 1212/4885 |
| US-12122859-B2 | Hydrophilic polymeric particles and methods for making and using same | CD44, CD68, MTDH | USP2 336/4885SMN1; SMN2 2622/4885TGM2 2799/4885 |
| US-20230348423-A1 | PYRIMIDINEDIONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF | MERTK, AXL, MET | USP2 4335/4885SMN1; SMN2 3855/4885TGM2 2008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.